Clinical Trials Logo

Clinical Trial Summary

Background: - Pomalidomide is a drug that can treat cancer through several mechanisms. It is taken by mouth (orally). Pomalidomide can help treat cancer by blocking certain factors that promote tumor growth or by stimulating the immune system to attack tumor cells. It also prevents the growth of new blood vessels that help cancer grow. Researchers want to see if pomalidomide can treat Kaposi sarcoma, a rare and potentially fatal skin cancer. Because Kaposi sarcoma may be associated with human immunodeficiency virus (HIV) infection, researchers want to test the drug in people with and without HIV infection. Objectives: - To see if pomalidomide is a safe and effective treatment for Kaposi sarcoma in people with or without HIV. Eligibility: - Individuals at least 18 years of age who have Kaposi sarcoma. - Participants may or may not have HIV infection. Design: - Potential participants will be screened with a medical history and physical exam. Blood and saliva samples will be taken and a chest X-ray will be performed. A skin biopsy of a Kaposi sarcoma lesion may be performed if one has not already been done. Other imaging studies may be performed if needed. - Participants will take pomalidomide capsules every day for 3 weeks, followed by a 1-week break. These 28 days are one cycle of treatment. - Participants will have up six cycles of treatment, unless the lesions completely resolve sooner. If there are signs of improvement after six cycles but the lesions are not completely gone, up to another six cycles of treatment may be given. - Treatment will be monitored with frequent blood tests and other studies including photograph and other imaging of skin lesions. - Participants will have regular follow-up visits for 5 years after stopping treatment....


Clinical Trial Description

Background: Kaposi Sarcoma (KS) is an incurable, multicentric angioproliferative tumor that most frequently involves the skin. It is seen most frequently in people with human immunodeficiency virus (HIV) or other forms of immune compromise. Current therapies are limited by toxicities, including cumulative cardiotoxicity, while effective oral agents, agents deliverable in resource-limited settings, and agents deliverable long-term for relapsing disease are all lacking. Objective: The primary objective of this study is to: Assess the safety, tolerability and pharmacokinetics of pomalidomide in subjects with Kaposi sarcoma, whether HIV associated or not. Eligibility: - Age greater than or equal to 18 years - Measurable, pathologically confirmed KS - Any HIV status; HIV-associated KS subjects must be receiving and able to comply with highly active antiretroviral therapy (HAART) and have achieved an HIV viral load <10,000 copies/mL - Hematologic and biochemical parameters within prespecified limits at baseline - Willing to use effective birth control, as defined in the full protocol - For subjects enrolled in the anti-tumor activity assessment phase, if KS is HIV-associated it must be increasing despite HAART and HIV suppression for greater than or equal to 2 months, or stable despite HAART for greater than or equal to 3 months - No symptomatic pulmonary or visceral KS - No specific KS therapy within 4 weeks (6 weeks if that therapy was bevacizumab) - Neither pregnant nor breast feeding Design: This is an open label single agent phase I/II study of pomalidomide in patients with KS. In the phase I portion, up to six subjects will initially be treated with pomalidomide 5mg daily for 21 days of a 28 day cycle. Subject to toxicity evaluation, this dosage may be deescalated to 3mg daily for 21 days of a 28 day cycle in a second cohort of up to six subjects. If either dose proves tolerable, the study will proceed to the phase II portion, and additional subjects to a goal of 15 HIV positive and 10 HIV negative subjects evaluable for response will be added at the highest tolerable dose to gain preliminary information on activity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01495598
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase Phase 1/Phase 2
Start date January 10, 2012
Completion date May 17, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed NCT00923936 - Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma Phase 2
Completed NCT00006310 - KSHV Infection in Blood Donors From Texas N/A
Active, not recruiting NCT00002318 - A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Phase 3
Completed NCT00002185 - A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3 Phase 2
Completed NCT00002259 - Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Phase 2
Completed NCT00002212 - A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma Phase 2
Completed NCT00002188 - A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma Phase 2
Completed NCT00000996 - A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma Phase 2
Completed NCT00000954 - A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma Phase 1
Completed NCT00001113 - A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma Phase 1
Completed NCT00002366 - The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma Phase 2
Completed NCT00002131 - A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma Phase 2
Completed NCT00002153 - Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders Phase 1
Completed NCT00000763 - A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma Phase 1
Completed NCT00002314 - A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma Phase 2
Completed NCT00000695 - Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma Phase 1
Completed NCT00002439 - A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma N/A
Completed NCT00002226 - Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma N/A
Completed NCT00002342 - A Study of Tecogalan Sodium Phase 1